EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design characteristics of mass balance studies conducted for protein kinase inhibitors

Benthe Riechelman, Ramon Bolks, Thijs H Oude Munnink, Jesse J Swen, Frank G A Jansman, Frank Klont

Cancer Chemotherapy and Pharmacology · 13.07.2026 · 96 (1)

DOI: 10.1007/s00280-026-04926-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 13.07.2026. Verfasst von Benthe Riechelman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, Groni…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organisation for Scientific Research, NWO (Applied and Engineering Sciences domain).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Protein kinase inhibitor (PKI) therapy increasingly relies on personalized approaches such as therapeutic drug monitoring and pharmacogenetic testing. Understanding PKI metabolism is essential for these methods to be effective, notably for determining the substance to be quantified and the enzyme for which the genotypic metabolizer status needs to be predicted. For most drugs, however, human in vivo metabolite profiles are derived from the mass balance studies conducted by drug developers, typically in small and homogeneous populations.

Methods

We studied mass balance study characteristics for PKIs, assessing number of participants, sex, and health state, as well as dosing regimen, study location, study duration, and consideration of genetic variation in metabolic enzymes and transporters. Data were primarily extracted from European Public Assessment Reports, supplemented with information from the Drugs@FDA database, ClinicalTrials.gov, and peer-reviewed mass balance study publications.

Results

Mass balance studies were conducted for 68 out of the 69 PKIs listed as “authorized” human drugs in the European Medicines Agency database on July 7, 2025 (updated April 18, 2026; +3 PKIs). The studies included 2–12 participants (median = 6), with 90% enrolling only healthy volunteers, 88% enrolling only males, 97% administering a single dose, and four studies mentioning consideration of genetic variation in metabolic enzymes during participant inclusion.

Conclusion

PKI mass balance studies exhibit similar, rather homogeneous design characteristics, potentially limiting the generalizability of their insights into drug metabolism across diverse patient populations. Still, most align with recent FDA guidelines on mass balance studies, despite being issued after study conduct.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsHumansMaleFemaleDrug MonitoringResearch Design

Stichwörter der Autor:innen

CancerDrug metabolismPharmacokineticsProtein kinase inhibitors

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Unit of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713 AV, The Netherlands.
  • Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), Weiersstraat 1C, Assen, 9401 ET, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9700 RB, The Netherlands.
  • Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands.
  • Department of Clinical Pharmacy, Deventer Hospital, Nico Bolkesteinlaan 75, Deventer, 7416 SE, The Netherlands.
  • Unit of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, Groningen, 9713 AV, The Netherlands. frank.klont@rug.nl.

Förderung

  • Netherlands Organisation for Scientific Research, NWO (Applied and Engineering Sciences domain)

Zitieren

APA

Riechelman, B., Bolks, R., Oude Munnink, T. H., Swen, J. J., Jansman, F. G. A., & Klont, F. (2026). Design characteristics of mass balance studies conducted for protein kinase inhibitors. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04926-5

Vancouver

Riechelman B, Bolks R, Oude Munnink TH, Swen JJ, Jansman FGA, Klont F. Design characteristics of mass balance studies conducted for protein kinase inhibitors. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04926-5

BibTeX
@article{Riechelman2026,
  author = {Riechelman, Benthe and Bolks, Ramon and Oude Munnink, Thijs H and Swen, Jesse J and Jansman, Frank G A and Klont, Frank},
  title = {Design characteristics of mass balance studies conducted for protein kinase inhibitors},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04926-5}
}
Kostenlos starten →